<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00357877</url>
  </required_header>
  <id_info>
    <org_study_id>DE017753-01</org_study_id>
    <secondary_id>U01DE017753</secondary_id>
    <nct_id>NCT00357877</nct_id>
  </id_info>
  <brief_title>Prevention of Adult Caries Study (PACS)</brief_title>
  <official_title>Prevention of Adult Caries Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Dental and Craniofacial Research (NIDCR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adult tooth decay is an infectious disease that afflicts the majority of Americans aged 55
      and older and is the most common chronic disease at midlife with an ever growing economic
      toll. Despite the fact that specific bacteria cause tooth decay, no FDA-approved
      anti-microbial treatment for decay is available to the American dental professional. The
      Prevention of Adult Caries Study (PACS) is a study designed to evaluate the efficacy of a
      topical, temporary, 10% w/v chlorhexidine dental coating in reducing new decay in adult
      dental patients at risk for decay.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Prevention of Adult Caries Study (PACS) is a randomized, double-blind, placebo-controlled
      Phase III clinical trial conducted under F.D.A. Investigational New Drug license #45,466,
      with a target enrollment of 1000 at four clinical centers with vastly different populations.
      The centers participating in this proposed research are: Kaiser Permanente's Dental Plan in
      Portland, Oregon; Tufts University Dental Clinic in central Boston, Massachusetts; Delta
      Dental Massachusetts' Dental Clinic in Southborough, Massachusetts; and the dental clinic of
      the Tuba City Regional Health Care Corporation in Tuba City, Arizona. Kaiser Permanente's
      Center for Health Research in Portland, Oregon will act as the data-coordinating center, and
      Tufts University will act as the Administrative Center. This study is designed to evaluate
      the efficacy of a topical, temporary, 10% w/v chlorhexidine dental coating in reducing caries
      increment in at-risk adult dental patients. This study will treat participants in months 1(4
      weekly applications) and 7(1 application) with final outcome measured at 13 months after
      randomization. Examiners were trained and certified before data collection started and were
      recalibrated annually. The primary outcome analysis in the intent -to- treat sample compares
      active to placebo group on the rank-normalized caries increment score, adjusting for
      examiner, age and age squared. Multiple imputation (data augmentation using MCMC) will be
      used to replace missing outcome. Planned secondary analysis examine the secondary caries
      increment outcomes using the same model, as well as parallel analyses in the per-protocol
      group. Safety of the coating will be evaluated by comparing development of resistant S.
      mutans or C. albicans as well as incidence of MedDRA-coded adverse events between the two
      arms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Net D12FS Caries Increment (Total of Non-cavitated Lesions (D1), Cavitated Lesions (D2) and Sound Surfaces (S))</measure>
    <time_frame>(V1) to the 13 month follow-up visit</time_frame>
    <description>Study duration was too short to have progression from D2 (cavitated lesions) to D3 (cavitated lesions that involved dentin). D2 and D3 were treated equivalently for analysis.
This measure is computed as the sum of weighted counts of transitions in tooth surface status (root and coronal surfaces combined) from randomization to the 13-month follow-up visit. Disease progression had a positive weight (e.g., S-to-D1 (sound to non-cavitated lesion) or D1-to-D2 (non-cavitated to cavitated lesion) = 1, S-to-D2 (sound to cavitated lesion)= 2). Reversal had a negative weight (e.g., D1-to-S = −1). No change, transitions to or from missing or unscorable, and impossible transitions had 0 weight. Incident fillings and crowns were treated the same as incident D2 lesions for purposes of scoring. More details of the transition weights may be found at Vollmer WM et al. (2010). Design of the Prevention of Adult Caries Study (PACS): a randomized clinical trial assessing the effect of a</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative Net D12FS Caries Increment</measure>
    <time_frame>Visit 1, 7-month follow-up, 13-month follow-up</time_frame>
    <description>This measure was computed similar to the total net D12FS increment, but separately scored and combined transitions from the baseline to 7-month visits and from the 7- to 13-month visits, rather than simply looking at the baseline to 13-month visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Crude D12FS Caries Increment</measure>
    <time_frame>V1-13-month follow-up</time_frame>
    <description>Computed analogous to the total net D12FS caries increment, but ignoring reversals (essentially assigned them zero weight). Computed only using baseline to 13-month visit data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Crude D12FS Caries Increment</measure>
    <time_frame>Visit 1, 7-month follow-up, 13-month follow-up</time_frame>
    <description>This is computed analogous to the cumulative net D12FS increment, but ignoring reversals by assigning them weights of zero.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">983</enrollment>
  <condition>Caries, Dental</condition>
  <arm_group>
    <arm_group_label>Placebo Dental Coating</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dental coating with all ingredients except Chlorhexidine topically applied by dental professional supragingivally to the full dentition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Dental Coating</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10% w/v chlorhexidine acetate coating FDA IND #45466. Dental coating with all ingredients including Chlorhexidine topically applied by dental professional supragingivally to the full dentition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10% w/v chlorhexidine acetate coating FDA IND #45466</intervention_name>
    <description>Dental coating topically applied by dental professional supragingivally to the full dentition</description>
    <arm_group_label>Active Dental Coating</arm_group_label>
    <other_name>CHX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo Dental Coating</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age and older

          -  at least 20 intact natural teeth, excluding third molars

          -  2 or more lesions, of which at least one must be a cavitated D2 or D3

          -  willing and able to provide informed consent

        Exclusion Criteria

          -  pregnant or planning to become pregnant or planning to become pregnant during the
             study (breastfeeding is permitted)

          -  use of fixed orthodontic appliances

          -  allergic to any of the ingredients of the study medication

          -  long-term antibiotic therapy

          -  a history of, or currently active, radiation therapy for cancers of the head or neck

          -  Sjögren's syndrome

          -  advanced periodontitis

          -  consumption of the equivalent of more than five servings of acidic or sugared drinks
             per day

          -  having 10 or more lesions requiring restorative care at the time of the screening
             visit

          -  remineralization therapy within one month of randomization

          -  investigator discretion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Athena Papas, PhD DMD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts University of Dental Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tuba City Regional Health Care</name>
      <address>
        <city>Tuba City</city>
        <state>Arizona</state>
        <zip>86045-0600</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts University School of Dental Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dental Services of Massachusetts</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Health Research</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Papas AS, Vollmer WM, Gullion CM, Bader J, Laws R, Fellows J, Hollis JF, Maupomé G, Singh ML, Snyder J, Blanchard P; PACS Collaborative Group. Efficacy of chlorhexidine varnish for the prevention of adult caries: a randomized trial. J Dent Res. 2012 Feb;91(2):150-5. doi: 10.1177/0022034511424154. Epub 2011 Dec 7.</citation>
    <PMID>22156917</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2006</study_first_submitted>
  <study_first_submitted_qc>July 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2006</study_first_posted>
  <results_first_submitted>October 18, 2016</results_first_submitted>
  <results_first_submitted_qc>May 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2017</results_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dental Caries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Dental Coating</title>
          <description>Dental coating with all ingredients except Chlorhexidine topically applied by dental professional supragingivally to the full dentition</description>
        </group>
        <group group_id="P2">
          <title>Active Dental Coating (CHX)</title>
          <description>Dental coating with all ingredients including Chlorhexidine topically applied by dental professional supragingivally to the full dentition. 10% w/v chlorhexidine acetate coating FDA IND #45466.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="493"/>
                <participants group_id="P2" count="490"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="467"/>
                <participants group_id="P2" count="460"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Dental Coating</title>
          <description>Dental coating with all ingredients except Chlorhexidine topically applied by dental professional supragingivally to the full dentition</description>
        </group>
        <group group_id="B2">
          <title>Active Dental Coating</title>
          <description>Dental coating with all ingredients including Chlorhexidine topically applied by dental professional supragingivally to the full dentition</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="493"/>
            <count group_id="B2" value="490"/>
            <count group_id="B3" value="983"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="463"/>
                    <measurement group_id="B2" value="459"/>
                    <measurement group_id="B3" value="922"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.8" spread="14.3"/>
                    <measurement group_id="B2" value="42.9" spread="14.3"/>
                    <measurement group_id="B3" value="42.8" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="242"/>
                    <measurement group_id="B2" value="250"/>
                    <measurement group_id="B3" value="492"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="251"/>
                    <measurement group_id="B2" value="240"/>
                    <measurement group_id="B3" value="491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="493"/>
                    <measurement group_id="B2" value="490"/>
                    <measurement group_id="B3" value="983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Net D12FS Caries Increment (Total of Non-cavitated Lesions (D1), Cavitated Lesions (D2) and Sound Surfaces (S))</title>
        <description>Study duration was too short to have progression from D2 (cavitated lesions) to D3 (cavitated lesions that involved dentin). D2 and D3 were treated equivalently for analysis.
This measure is computed as the sum of weighted counts of transitions in tooth surface status (root and coronal surfaces combined) from randomization to the 13-month follow-up visit. Disease progression had a positive weight (e.g., S-to-D1 (sound to non-cavitated lesion) or D1-to-D2 (non-cavitated to cavitated lesion) = 1, S-to-D2 (sound to cavitated lesion)= 2). Reversal had a negative weight (e.g., D1-to-S = −1). No change, transitions to or from missing or unscorable, and impossible transitions had 0 weight. Incident fillings and crowns were treated the same as incident D2 lesions for purposes of scoring. More details of the transition weights may be found at Vollmer WM et al. (2010). Design of the Prevention of Adult Caries Study (PACS): a randomized clinical trial assessing the effect of a</description>
        <time_frame>(V1) to the 13 month follow-up visit</time_frame>
        <population>Intention to treat (ITT) sample. Multiple imputation with 8 datasets imputed via Markov Chain Monte Carlo sampling was used to handle missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received a placebo dental coating containing no chlorhexidine diacetate (CHX).</description>
          </group>
          <group group_id="O2">
            <title>Active</title>
            <description>Participants received a dental coating containing chlorhexidine diacetate (CHX) 10% weight per volume.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Net D12FS Caries Increment (Total of Non-cavitated Lesions (D1), Cavitated Lesions (D2) and Sound Surfaces (S))</title>
          <description>Study duration was too short to have progression from D2 (cavitated lesions) to D3 (cavitated lesions that involved dentin). D2 and D3 were treated equivalently for analysis.
This measure is computed as the sum of weighted counts of transitions in tooth surface status (root and coronal surfaces combined) from randomization to the 13-month follow-up visit. Disease progression had a positive weight (e.g., S-to-D1 (sound to non-cavitated lesion) or D1-to-D2 (non-cavitated to cavitated lesion) = 1, S-to-D2 (sound to cavitated lesion)= 2). Reversal had a negative weight (e.g., D1-to-S = −1). No change, transitions to or from missing or unscorable, and impossible transitions had 0 weight. Incident fillings and crowns were treated the same as incident D2 lesions for purposes of scoring. More details of the transition weights may be found at Vollmer WM et al. (2010). Design of the Prevention of Adult Caries Study (PACS): a randomized clinical trial assessing the effect of a</description>
          <population>Intention to treat (ITT) sample. Multiple imputation with 8 datasets imputed via Markov Chain Monte Carlo sampling was used to handle missing data.</population>
          <units>weighted increment units/13 months</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="493"/>
                <count group_id="O2" value="490"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.43" spread="0.32"/>
                    <measurement group_id="O2" value="2.68" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We hypothesized a lower increment score for the active treatment group but carried out two-tailed hypothesis testing. Sample size was estimated with simulated data with rank normalized scores. We calculated that 832 participants would yield a power of 90% to detect a 20% reduction in caries incidence (from a hypothesized mean increment of 1.5), and adopted a target of 1000 randomized participants to allow for attrition.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.56</p_value>
            <p_value_desc>No interim analyses were done and no adjustment made for multiple comparisons. Identical analyses were run on each imputed dataset, with results combined with SAS® PROC MIANALZE to obtain final p-values.</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>The primary outcome analysis included treatment and site as class variables and age and age-squared as continuous covariates.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.60</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Net D12FS Caries Increment</title>
        <description>This measure was computed similar to the total net D12FS increment, but separately scored and combined transitions from the baseline to 7-month visits and from the 7- to 13-month visits, rather than simply looking at the baseline to 13-month visits.</description>
        <time_frame>Visit 1, 7-month follow-up, 13-month follow-up</time_frame>
        <population>Intention-to-Treat sample</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Dental Coating</title>
            <description>Dental coating with all ingredients except Chlorhexidine topically applied by dental professional supragingivally to the full dentition</description>
          </group>
          <group group_id="O2">
            <title>Active Dental Coating (CHX)</title>
            <description>Dental coating with all ingredients including Chlorhexidine topically applied by dental professional supragingivally to the full dentition. 10% w/v chlorhexidine acetate coating FDA IND #45466.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Net D12FS Caries Increment</title>
          <description>This measure was computed similar to the total net D12FS increment, but separately scored and combined transitions from the baseline to 7-month visits and from the 7- to 13-month visits, rather than simply looking at the baseline to 13-month visits.</description>
          <population>Intention-to-Treat sample</population>
          <units>caries increment units/13 months</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="493"/>
                <count group_id="O2" value="490"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.53" spread="0.42"/>
                    <measurement group_id="O2" value="5.88" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>hypothesized a reduced caries increment in active arm, though conducted two-tailed hypothesis test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.54</p_value>
            <p_value_desc>No adjustment for multiple comparisons. Identical analyses were run on each imputed dataset, with results combined with SAS® PROC MIANALYZE to obtain final p-values.</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>Model included treatment and site as class variables and age and age-squared as continuous covariates.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.57</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.77</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Crude D12FS Caries Increment</title>
        <description>Computed analogous to the total net D12FS caries increment, but ignoring reversals (essentially assigned them zero weight). Computed only using baseline to 13-month visit data.</description>
        <time_frame>V1-13-month follow-up</time_frame>
        <population>Intention-to-Treat sample</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Dental Coating</title>
            <description>Dental coating with all ingredients except Chlorhexidine topically applied by dental professional supragingivally to the full dentition</description>
          </group>
          <group group_id="O2">
            <title>Active Dental Coating (CHX)</title>
            <description>Dental coating with all ingredients including Chlorhexidine topically applied by dental professional supragingivally to the full dentition. 10% w/v chlorhexidine acetate coating FDA IND #45466.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Crude D12FS Caries Increment</title>
          <description>Computed analogous to the total net D12FS caries increment, but ignoring reversals (essentially assigned them zero weight). Computed only using baseline to 13-month visit data.</description>
          <population>Intention-to-Treat sample</population>
          <units>caries increment units/13 months</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="493"/>
                <count group_id="O2" value="490"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.47" spread="0.27"/>
                    <measurement group_id="O2" value="5.96" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesized lower increment in active arm, though hypothesis testing was two-sided.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <p_value_desc>No adjustment for multiple comparisons. Identical analyses were run on each imputed dataset, with results combined with SAS® PROC MIANALYZE to obtain final p-values.</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>treatment and site included as class variables and age and age-squared as continuous covariates.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.38</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.25</ci_lower_limit>
            <ci_upper_limit>0.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Crude D12FS Caries Increment</title>
        <description>This is computed analogous to the cumulative net D12FS increment, but ignoring reversals by assigning them weights of zero.</description>
        <time_frame>Visit 1, 7-month follow-up, 13-month follow-up</time_frame>
        <population>Intention-to-Treat sample</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Dental Coating</title>
            <description>Dental coating with all ingredients except Chlorhexidine topically applied by dental professional supragingivally to the full dentition</description>
          </group>
          <group group_id="O2">
            <title>Active Dental Coating (CHX)</title>
            <description>Dental coating with all ingredients including Chlorhexidine topically applied by dental professional supragingivally to the full dentition. 10% w/v chlorhexidine acetate coating FDA IND #45466.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Crude D12FS Caries Increment</title>
          <description>This is computed analogous to the cumulative net D12FS increment, but ignoring reversals by assigning them weights of zero.</description>
          <population>Intention-to-Treat sample</population>
          <units>caries increment units/13 months</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="493"/>
                <count group_id="O2" value="490"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.39" spread="0.42"/>
                    <measurement group_id="O2" value="10.72" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesized a lower increment for active treatment arm, although hypothesis testing was two-sided.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <p_value_desc>No adjustment for multiple comparisons. Identical analyses were run on each imputed dataset, with results combined with SAS® PROC MIANALYZE to obtain final p-values.</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>Model included treatment and site as class variables, and age and age-squared as continuous covariates.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.68</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.57</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.80</ci_lower_limit>
            <ci_upper_limit>0.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported at any time throughout the study and were systematically screened for at the 6-month and 1-year visit.</time_frame>
      <desc>Systematic assessment of adverse events evaluated during routine completion of standard questionnaire.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received a placebo dental coating containing no chlorhexidine diacetate (CHX).</description>
        </group>
        <group group_id="E2">
          <title>Active</title>
          <description>Participants received a dental coating containing chlorhexidine diacetate (CHX) 10% weight per volume.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Cellulitis of male external genital organ</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Lung injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Traumatic liver injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Cervical spine stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Trismus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Benign pancreatic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Head and neck cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral ventricle dilation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Exposure to communicable disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Gastric bypass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Hernia repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Rectal fistula repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Urinary bladder excision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sensitivity of teeth</sub_title>
                <counts group_id="E1" events="36" subjects_affected="32" subjects_at_risk="493"/>
                <counts group_id="E2" events="29" subjects_affected="26" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="44" subjects_affected="43" subjects_at_risk="493"/>
                <counts group_id="E2" events="31" subjects_affected="30" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Pharmaceutical product complaint</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="493"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. William Vollmer</name_or_title>
      <organization>Kaiser Permanente Data Coordinating Center</organization>
      <phone>503-335-6755</phone>
      <email>william.vollmer@kpchr.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

